The Use of Recombinant Human Erythropoietin in the Correction of Anemia in Predialysis Patients and Its Effect on Renal Function: A Double-Blind, Placebo-Controlled Trial
- 1 December 1989
- journal article
- clinical trial
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 14 (6) , 486-495
- https://doi.org/10.1016/s0272-6386(89)80149-0
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Creatinine measurements often yield false estimates of progression in chronic renal failureKidney International, 1988
- Correction of the Anemia of End-Stage Renal Disease with Recombinant Human ErythropoietinNew England Journal of Medicine, 1987
- EFFECT OF HUMAN ERYTHROPOIETIN DERIVED FROM RECOMBINANT DNA ON THE ANAEMIA OF PATIENTS MAINTAINED BY CHRONIC HAEMODIALYSISThe Lancet, 1986
- Anemia of end-stage renal disease (ESRD)Kidney International, 1985
- Isolation and characterization of genomic and cDNA clones of human erythropoietinNature, 1985
- Assessment of the quality of life of patients with advanced cancerEuropean Journal of Cancer and Clinical Oncology, 1983
- A SIMPLE METHOD OF ESTIMATING PROGRESSION OF CHRONIC RENAL FAILUREThe Lancet, 1976
- Iron Absorption in Patients with Chronic Renal Failure not Requiring Dialytic TherapyActa Medica Scandinavica, 1975
- Characterization of the anemia associated with chronic renal insufficiencyThe American Journal of Medicine, 1958
- ANEMIA IN AZOTEMIAThe Lancet Healthy Longevity, 1933